NCT02115074 2026-03-18
FLUVABREX
Centre Oscar Lambret
Phase 1 Completed
Clinical Trials
10 trialsNCT07416188 2026-03-18
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
NCT06161519 2026-03-17
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05588141 2026-03-13
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT01356290 2026-02-23
MEMMAT
Medical University of Vienna
Phase 2 Recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02942264 2026-02-23
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT07424092 2026-02-20
PED-DNX2401
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Not yet recruiting